/
ANAB
$56.02-$0.96 (-1.68%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$1.7B
30M shares
52-week range
$17.11 – $73.30
69% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change+$32.39
AnaptysBio, Inc. Common Stock
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
www.anaptysbio.com- Employees
- 104
- IPO / List date
- Jan 26, 2017
- HQ
- SAN DIEGO, CA
Held by traders on TradeandTell
No one on the platform currently holds ANAB.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 90,900 | $5.0M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ANAB yet.
